Clinical Trial Update: Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS

View source ↗

Summary

This document notes an expanded access program for Galinpepimut-S (GPS) in patients with acute myeloid leukemia or myelodysplastic syndromes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Galinpepimut-S (GPS) (Galinpepimut-S)

Snippet

Sponsor: Sellas Life Sciences Group | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes | Status: AVAILABLE